 Mustang Bio Inc NASDAQ: MBIO has updated interim data from the ongoing Phase 12 trial evaluating MB-106 for high-risk B-cell non-Hodgkin lymphomas B-NHL and chronic lymphocytic leukemia CLL. The data were presented at the European Hematology Association 2021 Virtual Congress. 